South Africa has a three- to five-year window to enter and establish a strong position in the European medical cannabis market, before it is outstripped by hungrier and quicker competitors from Latin America and parts of Asia, and other lowcost producers.
“Initially it was only in Italy and the Netherlands that patients could access products, but that is changing fast,” says Stephen Murphy, cofounder and CEO of Prohibition Partners. Germany is now the largest and most developed of the European markets, with a wide variety of products sold, he says. Consumer appetite for the products is growing fast – with 200,000 patients in Germany accessing medical cannabis products in 2021, up from 20,000 the previous year.
The study was commissioned and funded by the EU-SA Partners for Growth project, which is aimed at maximising trade and investment between Europe and SA. However, some Lesotho-based companies are taking advantage of the enabling regulatory environment there and are further ahead when it comes to positioning themselves for the European market.
As a result MG Health which was already supplying into Germany, has expanded into other European markets.
Slow only because the cANCer haven't figured out how to steal money from that yet.
Interpol website under Red Notices. Guptas are not there mos, why?